Leaflet BOOSTRIX suspension for injection in pre-filled syringe


Indicated for: prevention of diphtheria, tetanus and pertussis

Route of administration: injectable

Substance: diphtheria, tetanus, pertussis vaccine (vaccine)

ATC: J07AJ52 (Antiinfectives for systemic use | Bacterial vaccines | Pertussis vaccines)

The diphtheria, tetanus, pertussis (DTP) vaccine is used to prevent diphtheria, tetanus, and whooping cough, three serious infectious diseases caused by bacteria. The vaccine contains diphtheria and tetanus toxoids, as well as inactivated or purified components of Bordetella pertussis, which stimulate the immune system to produce specific antibodies against these pathogens.

The vaccine is administered intramuscularly, usually in multiple doses, according to recommended vaccination schedules for infants, children, and adolescents. Booster doses are required at regular intervals to maintain immunity.

Common side effects include pain at the injection site, mild fever, fatigue, and irritability. In rare cases, severe allergic reactions may occur.

The DTP vaccine is an essential measure for protecting public health, helping to reduce the incidence and severity of these infectious diseases and prevent the severe complications associated with them.

General data about BOOSTRIX

  • Substance: diphtheria, tetanus, pertussis vaccine
  • Date of last drug list: 01-02-2021
  • Commercial code: W67291001
  • Pharmaceutical form: suspension for injection in pre-filled syringe
  • Quantity: 1
  • Product type: original
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: GLAXOSMITHKLINE BIOLOGICALS SA - BELGIA
  • Holder: GLAXOSMITHKLINE (GSK) S.R.L. - ROMANIA
  • Number: 12980/2020/01
  • Shelf life: 3 years